At the time of writing, Maze Therapeutics Inc [MAZE] stock is trading at $26.35, up 0.65%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MAZE shares have gain 12.22% over the last week, with a monthly amount glided 87.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maze Therapeutics Inc [NASDAQ: MAZE] stock has seen the most recent analyst activity on September 02, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $30. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 23, 2025, and set its price target to $34. On July 08, 2025, Wedbush initiated with a Outperform rating and assigned a price target of $17 on the stock.
For the past year, the stock price of Maze Therapeutics Inc fluctuated between $6.71 and $27.65. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Maze Therapeutics Inc [NASDAQ: MAZE] shares were valued at $26.35 at the most recent close of the market. An investor can expect a potential return of 2.47% based on the average MAZE price forecast.
Analyzing the MAZE fundamentals
Gross Profit Margin for this corporation currently stands at 0.18% with Operating Profit Margin at -50.33%, Pretax Profit Margin comes in at -48.54%, and Net Profit Margin reading is -48.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 11.67 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.61 points at the first support level, and at 24.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.38, and for the 2nd resistance point, it is at 28.41.
Ratios To Look Out For
It is important to note that Maze Therapeutics Inc [NASDAQ:MAZE] has a current ratio of 13.63. Also, the Quick Ratio is 13.63, while the Cash Ratio stands at 13.29. Considering the valuation of this stock, the price to sales ratio is 462.19, the price to book ratio is 4.41.
Transactions by insiders
Recent insider trading involved SCHELLER RICHARD H, Director, that happened on Sep 15 ’25 when 20744.0 shares were sold. Director, RICHARD SCHELLER completed a deal on Sep 15 ’25 to buy 20744.0 shares.
